Healio Minute Podcast, Gastroenterology Edition: Top Headlines - Week of October 24, 2022
Click Here to Manage Email Alerts
In this edition, AGA speaks out on controversial NordICC data; first US patient enrolled in phase 3 trial of obefazimod; ‘unprecedented’ shift in hepatitis A outbreaks and more.
Read the full coverage here:
AGA speaks out on controversial NordICC data citing modest colonoscopy benefit for CRC
First US patient enrolled in Abivax’s phase 3 trial of obefazimod for ulcerative colitis
Shift in hepatitis A outbreaks ‘unprecedented’ in HAV vaccine era, CDC reports
AGA releases first guideline ranking most effective anti-obesity medications
Inflammatory bowel disease may be causal risk for psoriasis, psoriatic arthritis
References:
Bretthauer M, et al. NEJM. 2022;doi:10.1056/NEJMoa2208375.
Foster MA, et al. MMWR Morb Mortal Wkly Rep. 2022;doi:10.15585/mmwr.mm7139a1.
Freuer D, et al. JAMA Dermatol. 2022;doi:10.1001/jamadermatol.2022.3682.
Grunvuld E, et al. Gastroenterology. 2022; doi: 10.1053/j.gastro.2022.08.045.
Collapse
Read more about
Click Here to Manage Email Alerts
